Edoxaban API

Mechanism of Action

Edoxaban is a direct oral anticoagulant (DOAC) that acts as a factor Xa inhibitor. It works by blocking the activity of factor Xa, a key component of the coagulation cascade.

Factor Xa plays a central role in the blood coagulation process, converting prothrombin to thrombin and leading to the formation of a blood clot. By inhibiting the activity of factor Xa, edoxaban helps to reduce the formation of blood clots and the risk of thromboembolic events such as stroke and deep vein thrombosis (DVT).

Edoxaban works differently from traditional anticoagulants such as warfarin, which work by blocking the recycling of vitamin K and the synthesis of coagulation factors. Unlike warfarin, edoxaban does not require frequent monitoring or dose adjustments and has a more predictable anticoagulant effect.

Overall, the mechanism of action of edoxaban involves the inhibition of factor Xa, leading to a reduction in the formation of blood clots and the risk of thromboembolic events.

Indication

Edoxaban is FDA-approved for the prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation (AF). It is also indicated for the treatment and reduction of risk of recurrence of deep vein thrombosis (DVT) and pulmonary embolism (PE).

Atrial Fibrillation: Edoxaban is indicated for the prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation who have one or more risk factors, such as age, congestive heart failure, hypertension, or previous stroke or transient ischemic attack (TIA).

Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE): Edoxaban is indicated for the treatment of DVT and PE, and for the reduction of the risk of recurrent DVT and PE following initial treatment with a parenteral anticoagulant.

Dr. Reddy's Expertise

Headquartered in Hyderabad, India, Dr. Reddy's Laboratories is one of the leading Active Pharmaceutical Ingredients (API) manufacturers and suppliers globally for Edoxaban API. Dr. Reddy's API business is a preferred partner to pharma companies across the US, Europe, Brazil, Latin America, Japan, China, Korea, Middle East and other emerging markets.

Dr. Reddy's API business thrives on the deep technical strengths established over the last 30+ years in the development and manufacture of complex APIs such as steroids, peptides, complex long chain molecules and highly potent APIs (HPAPIs / oncology drugs). This expertise is complemented by our prowess in intellectual property and regulatory affairs which helps us consistently meet and exceed regulatory standards. Dr. Reddy's Edoxaban API is the outcome of the extensive expertise in R&D, IP, and Regulatory.

A key component in helping our customers be first to market is a responsive supply chain. We achieve this by making sure that all our facilities are operating efficiently and to the latest standards of quality, safety, and productivity. A strong interconnect between business and factories allows for a quick reaction to dynamic market changes, so that we can avert shortages and meet sudden surges in demand.